Table 1.
Baseline demographic and clinical characteristics.
| Participants | N=17 |
|---|---|
|
| |
| Sex | |
| Male | 88 (15) |
| Female | 12 (2) |
|
| |
| Ethnicity | |
| African American | 24 (4) |
| Hispanic | 41 (7) |
| White | 35 (8) |
|
| |
| Age (years) | 60 (54, 63) |
|
| |
| BMI (kg/m2) | 27 (27, 30) |
|
| |
| Current tobacco use | 18 (3) |
|
| |
| Blood Pressure (mmHg) | |
| Systolic | 130 (122, 138) |
| Diastolic | 72 (66, 83) |
|
| |
| Framingham risk score (%) | 10 (7,12) |
|
| |
| CD4+ T lymphocyte count (cells/mm3) | 625 (413, 729) |
|
| |
| PI | 71 (12) |
| Atazanavir/ritonavir | 18 (3) |
| Atazanavir | 18 (3) |
| Darunavir/ritonavir | 18 (3) |
| Fosamprenavir/ritonavir | 6 (1) |
| Lopinavir/ritonavir | 12 (2) |
| NNRTI | 29 (5) |
| Efavirenz | 24 (4) |
| Nevirapine | 6 (1) |
| NRTI | 94 (16) |
| Abacavir | 29 (5) |
| Emtricitabine | 59 (10) |
| Lamivudine | 29 (5) |
| Tenofovir | 65 (11) |
| Zidovudine | 6 (1) |
| Integrase Inhibitor (raltegravir) | 29 (5) |
| Entry inhibitor (maraviroc) | 6 (1) |
|
| |
| Diabetes a | 12 (2) |
|
| |
| Hypertension a | 65 (11) |
|
| |
| Hyperlipidemia a | 82 (14) |
|
| |
| Lipodystrophya, b | 18 (3) |
Values are expressed as median (interquartile range) or n (%)
a
Defined as self-reported diagnosis or on-therapy at baseline
b
Defined as self-report of isolated lipoatrophy or lipohypertrophy or mixed lipoatrophy/lipohypertrophy
BMI: body mass index; PI: Protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor